BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29226858)

  • 1. The clinical significance of the combined detection of serum Smac, HE4 and CA125 in endometriosis-associated ovarian cancer.
    Xu XR; Wang X; Zhang H; Liu MY; Chen Q
    Cancer Biomark; 2018 Feb; 21(2):471-477. PubMed ID: 29226858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
    Azzam AZ; Hashad DI; Kamel NA
    Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA125 and HE4: Measurement Tools for Ovarian Cancer.
    Zhao T; Hu W
    Gynecol Obstet Invest; 2016; 81(5):430-5. PubMed ID: 27160726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
    Zheng H; Gao Y
    Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between Serum HE4 and CA125 as Tumor Markers in Premenopausal Women with Benign Pelvic Mass.
    Huang X; Wang Y; He X; Kang F; Luo L; Su Z; Ye H
    Clin Lab; 2019 May; 65(5):. PubMed ID: 31115211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
    Xi QP; Pu DH; Lu WN
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
    Li W; Wang D
    Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].
    Liu YN; Ye X; Cheng HY; Cheng YX; Fu TY; Chen J; Chang XH; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):363-6. PubMed ID: 20646446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ovarian cancer markers in endometriosis favours HE4 over CA125.
    Mckinnon B; Mueller MD; Nirgianakis K; Bersinger NA
    Mol Med Rep; 2015 Oct; 12(4):5179-84. PubMed ID: 26165164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass.
    Goff BA; Agnew K; Neradilek MB; Gray HJ; Liao JB; Urban RR
    Gynecol Oncol; 2017 Nov; 147(2):291-295. PubMed ID: 28860006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical value of the combined detection of sEGFR, CA125 and HE4 for epithelial ovarian cancer diagnosis.
    Li Y; Wang ZC; Luo L; Mu CY; Xu J; Feng Q; Li SB; Gu B; Ma P; Lan T
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):604-610. PubMed ID: 32016961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Establishment of an HE4-CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer.
    Zhang Q; Wang CR; Yu JP; Ma Q; Xu WW
    J Clin Lab Anal; 2016 Sep; 30(5):709-18. PubMed ID: 26990679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women.
    Yu S; Lee JK; Kim JH; Park H; Lee MY; Ryu S; Kwon MJ; Woo HY
    Gynecol Oncol; 2016 Oct; 143(1):128-134. PubMed ID: 27426308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and serum CA19-9 combined with HE4 are valuable in diagnosing endometriosis-associated ovarian cancer.
    Xu T; Zhang L; Jiang Y; Wan Y; Zhou S; Sun G; Cheng W; Yuan L
    Int J Gynaecol Obstet; 2023 Aug; 162(2):472-478. PubMed ID: 36708088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.